Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.80 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150387 | 0.90 | DYRK1A (0.81) | DYRK1A | |
| SCHEMBL23150317 | 0.89 | DYRK1A (1.00) | DYRK1AACHE | |
| SCHEMBL23150337 | 0.88 | DYRK1A (0.81) | DYRK1A | |
| SCHEMBL23150419 | 0.87 | DYRK1A (0.82) | DYRK1A | |
| SCHEMBL23150381 | 0.86 | DYRK1A (0.82) | DYRK1A | |
| SCHEMBL23150380 | 0.85 | DYRK1A (0.81) | DYRK1AACHE | |
| SCHEMBL23150383 | 0.84 | DYRK1A (0.80) | DYRK1AACHE | |
| SCHEMBL29424333 | 0.82 | DYRK1A (0.70) | DYRK1A | |
| SCHEMBL15241459 | 0.81 | DYRK1A (1.00) | DYRK1A | |
| SCHEMBL16421934 | 0.81 | DYRK1A (0.61) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| CN-112135613-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2020-12-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | DYRK1A 2/4885ACHE 745/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | DYRK1A 7/4885ACHE 831/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | DYRK1A 7/4885ACHE 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.